세계의 간질성 방광염 시장 보고서(2025년)
Interstitial Cystitis Global Market Report 2025
상품코드 : 1825422
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,586,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,520,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,454,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

간질성 방광염 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.8%로 27억 5,000만 달러로 성장할 전망입니다. 예측기간의 성장은 바이오마커 조사, 혁신적인 의약품, 환자 중심의 의료, 세계적인 전개에 기인할 것으로 예상됩니다. 예측기간의 주요 동향은 식습관 지도, 학제 간 관리, 연구 협력, 대체요법 등입니다.

향후 5년간의 예측 성장률 8.8%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과로 미국에서는 캐나다와 네덜란드에서 수입되는 방광유치술과 골반저근 바이오피드백 장비에 대한 접근에 지장이 발생하여 만성통증 관리가 악화되고 비뇨기과 부담이 증가할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.

요로감염(UTI)의 유병률 증가는 간질성 방광염 시장의 성장을 가속할 것으로 예측됩니다. 요로감염은 요도로 침입하는 박테리아에 의해 유발되며 비뇨기 시스템의 다양한 부분에 영향을 미치는 박테리아 감염입니다. 이러한 감염은 직접 또는 간접적으로 세균성 방광염으로 이어질 수 있으며 요로결석을 치료하지 않으면 간질성 방광염의 중요한 요인인 만성 방광염을 유발할 수 있습니다. 간질성 방광염과 관련된 요로결석을 치료하여 병에 걸린 환자의 통증을 완화하고 삶의 질을 향상시킬 수 있습니다. 예를 들어 2024년 1월 신장병의 인식, 예방, 치료를 전문으로 하는 미국 단체 National Kidney Foundation Inc.가 발표한 조사논문에 따르면 여성의 약 50%-60%가 일생 동안 한 번은 요로결석을 경험한다고 합니다. 이와 같이 요로결석의 발생이 증가하고 있는 것이 간질성 방광염 시장을 전진시킬 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Interstitial cystitis (IC) is a persistent condition characterized by bladder discomfort, pain, and pressure that can range from mild to severe, and may be constant or intermittent, lasting beyond six months. It involves the experience of distress, stress, or discomfort linked to the urinary bladder. The application of tricyclic antidepressants, antihistamines, and bladder instillations can provide relief from pain and inflammation.

The primary treatments for interstitial cystitis include medications, bladder instillation, botulinum toxin A, nerve stimulation, and surgical interventions. Interstitial cystitis medications encompass a range of drugs and therapeutic approaches employed to manage the symptoms of this chronic bladder inflammation condition. These treatments are designed for both pediatric and adult patients and encompass various drug types, including over-the-counter (OTC) and prescription medications. The end users of these treatments include hospitals, clinics, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The interstitial cystitis market research report is one of a series of new reports from The Business Research Company that provides interstitial cystitis market statistics, including interstitial cystitis industry global market size, regional shares, competitors with a interstitial cystitis market share, detailed interstitial cystitis market segments, market trends and opportunities and any further data you may need to thrive in the interstitial cystitis industry. This interstitial cystitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The interstitial cystitis market size has grown strongly in recent years. It will grow from $1.83 billion in 2024 to $1.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in diagnosis, awareness and education, pharmaceutical developments, supportive therapies.

The interstitial cystitis market size is expected to see strong growth in the next few years. It will grow to $2.75 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to biomarker research, innovative medications, patient-centered care, global expansion. Major trends in the forecast period include dietary guidance, interdisciplinary care, research collaboration, alternative therapies.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. access to bladder instillations and pelvic floor biofeedback devices imported from Canada and the Netherlands, potentially worsening chronic pain management and increasing urology department burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of urinary tract infections (UTIs) is anticipated to drive the growth of the interstitial cystitis market. UTIs are bacterial infections that affect various parts of the urinary system, caused by bacteria entering through the urethra. These infections can directly or indirectly lead to bacterial cystitis, and untreated UTIs may result in chronic bladder inflammation, a key factor in interstitial cystitis. Treating UTIs associated with interstitial cystitis helps relieve pain and improve quality of life for affected patients. For example, in January 2024, according to a research article published by the National Kidney Foundation Inc., a US-based organization dedicated to kidney disease awareness, prevention, and treatment, approximately 50%-60% of women experience a UTI at least once in their lifetime. Thus, the increasing occurrence of UTIs is expected to propel the interstitial cystitis market forward.

The burgeoning governmental initiatives are poised to propel the growth of the interstitial cystitis market. Government initiatives represent strategic plans or actions taken by governments to address specific issues or problems, often funded through various sources such as taxes, grants, and donations. In the context of interstitial cystitis (IC), government initiatives play a crucial role in supporting fundamental research to enhance the understanding of IC's causes and mechanisms. They also provide funding for clinical trials aimed at testing novel treatments and therapies. For instance, in June 2023, the Food and Drug Administration, a US-based federal agency responsible for public health protection, introduced an initiative focused on a drug development program for the treatment and the creation of products designed to address interstitial cystitis or bladder pain syndrome. Therefore, the increasing government initiatives drive the interstitial cystitis market.

Leading companies in the interstitial cystitis treatment market are focusing on launching new clinical trial phases to develop innovative treatments and boost market revenue. These advancements aim to improve care and outcomes for this chronic and often complex bladder condition. For example, in May 2023, Vaneltix Pharma, Inc. partnered with Prevail Infoworks, Inc. to initiate a Phase 2 clinical trial. This trial evaluates the safety and efficacy of VNX001 in comparison to its individual components (lidocaine and heparin) or a placebo for individuals with interstitial cystitis/bladder pain syndrome (IC/BPS). Actively recruiting participants, this collaboration merges pharmaceutical and analytics expertise to advance potential treatments for IC/BPS, underscoring a commitment to innovative healthcare solutions.

In June 2023, Ironwood Pharmaceuticals, a US-based pharmaceutical company, merged with VectivBio Holding AG for an undisclosed amount. This acquisition aims to strengthen Ironwood's gastrointestinal pipeline, specifically focusing on treatments for rare and underserved conditions. This strategic move aligns with Ironwood's objective to expand its presence in the gastrointestinal market by leveraging VectivBio's expertise in rare disease therapeutics. VectivBio Holding AG is a Switzerland-based clinical-stage biopharmaceutical company specializing in treatments for rare gastrointestinal diseases.

Major companies operating in the interstitial cystitis market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Sun Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim international GmbH, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Perrigo Company PLC, Aurobindo Pharma Ltd., Purdue Pharma LP, Apotex Inc., Endo International PLC, Amneal Pharmaceuticals Inc., Alvogen Inc., Kyorin Pharmaceutical Co. Ltd., Seikagaku Corp, Genentech Inc., Strides Pharma Science Limited, AlgoTherapeutix SAS.

North America was the largest region in the interstitial cystitis market in 2024. The regions covered in interstitial cystitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the interstitial cystitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interstitial cystitis market include revenues earned through entities by providing services such as physical therapy, oral medications, nerve stimulation and bladder distention. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Interstitial Cystitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on interstitial cystitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for interstitial cystitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interstitial cystitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Interstitial Cystitis Market Characteristics

3. Interstitial Cystitis Market Trends And Strategies

4. Interstitial Cystitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Interstitial Cystitis Growth Analysis And Strategic Analysis Framework

6. Interstitial Cystitis Market Segmentation

7. Interstitial Cystitis Market Regional And Country Analysis

8. Asia-Pacific Interstitial Cystitis Market

9. China Interstitial Cystitis Market

10. India Interstitial Cystitis Market

11. Japan Interstitial Cystitis Market

12. Australia Interstitial Cystitis Market

13. Indonesia Interstitial Cystitis Market

14. South Korea Interstitial Cystitis Market

15. Western Europe Interstitial Cystitis Market

16. UK Interstitial Cystitis Market

17. Germany Interstitial Cystitis Market

18. France Interstitial Cystitis Market

19. Italy Interstitial Cystitis Market

20. Spain Interstitial Cystitis Market

21. Eastern Europe Interstitial Cystitis Market

22. Russia Interstitial Cystitis Market

23. North America Interstitial Cystitis Market

24. USA Interstitial Cystitis Market

25. Canada Interstitial Cystitis Market

26. South America Interstitial Cystitis Market

27. Brazil Interstitial Cystitis Market

28. Middle East Interstitial Cystitis Market

29. Africa Interstitial Cystitis Market

30. Interstitial Cystitis Market Competitive Landscape And Company Profiles

31. Interstitial Cystitis Market Other Major And Innovative Companies

32. Global Interstitial Cystitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Interstitial Cystitis Market

34. Recent Developments In The Interstitial Cystitis Market

35. Interstitial Cystitis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기